Added 7 months ago Drug news
FDA approves Bijuva to treat moderate to severe vasomotor symptoms due to menopause. Therapeutics MD
Therapeutics MD, Inc. announced that the FDA has approved Bijuva (estradiol and progesterone) capsules, 1 mg/100 mg, the first and...
Added 8 months ago Drug news
TX 001HR for the treatment of moderate-to-severe vasomotor symptoms due to menopause has PDUFA date of 28 October 2018.- Therapeutics MD
Therapeutics MD, Inc. announced that the Company has entered into discussions with the FDA regarding the proposed label for TX...
Added 1 year ago Drug news
TherapeuticsMD has resubmitted the New Drug Application (NDA) for TX004HR (oestradiol).
An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.
The Cardiovascular Metabolism Knowledge Centre is an information hub providing expert insight into the management of hypertension and type 2 diabetes. This Knowledge Centre contains a wealth of scientific video content offering insights and opinion from some of the leading experts in the field.
See information on best practice in solid organ transplantation, and expert discussions on related hot topics.
The Atopic Dermatitis Knowledge Centre is an educational resource, intended for healthcare professionals, that provides credible medical information on the epidemiology, pathophysiology and burden of atopic dermatitis, as well as diagnostic techniques, treatment regimens and guideline recommendations.
This guideline covers the diagnosis and management of menopause, including in women who have premature ovarian insufficiency. The guideline aims to improve the consistency of support and information provided to women in menopause.
Added 3 years ago
Ospemifene is a selective estrogen receptor modulator used for the treatment of vulvo-vaginal atrophy (VVA) in post-menopausal women. No direct evidence of its effects on histological features of the human vagina has been reported.
Added 1 year ago
In the absence of a direct head-to-head study, we performed an indirect historical comparison of ospemifene 60 mg (Senshio®) vs. local vaginal estrogens in moderate or severe vulvar and vaginal atrophy (VVA).
Added 2 years ago
Clinical update on the use of ospemifene in the treatment of severe symptomatic vulvar and vaginal atrophy.
The physiological decrease in vaginal estrogens is accountable for the emergence of vulvar and vaginal atrophy (VVA) and its related symptoms such as vaginal dryness, dyspareunia, vaginal and/or vulvar irritation or itching, and dysuria.
Added 2 years ago
- Accrediting body
MIMS Learning - Monthly Index of Medical Specialities
- Credits available
- Registration required
- Subscription fee